In terms of disease diagnosis, quite a few of biomarkers, such as AFP- L3 for hepatocellular carcinoma (HCC), MUC1 (CA15-3) for breast cancer, MUC16 (CA125) for ovarian cancer, WFA-MUC1 for cholangiocarcinoma, and PSA for prostate cancer, are also developed in dependence of the alterations of glycans on the core protein [18,19,20,21]. This evidence concerns the gene MUC16 and prostate cancer.